Vaxxas

Vaxxas is a clinical-stage private biotechnology company pioneering its proprietary high-density microarray patch (HD-MAP) for needle-free vaccine delivery. The HD-MAP has been administered to more than 750 participants across multiple clinical trials, showing strong safety, tolerability, and robust immune responses. Preclinical and clinical data d... emonstrate the technologys ability to deliver all major vaccine modality types including live attenuated, protein subunit, and mRNA positioning the platform as a universal delivery solution. By targeting immune cells just beneath the skin, the HD-MAP can achieve stronger protection with smaller doses, while reducing cold-chain requirements and enabling self-administration. With the potential to disrupt the multibillion-dollar global vaccine market by improving access, reducing costs, and expanding coverage, Vaxxas is now scaling manufacturing and advancing its lead programs toward commercialisation from its base in Brisbane, AustraliaRead More